Related Experiment Video

Updated: Jun 3, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so,

Per Winkel1, Jørgen Hilden, Jørgen Fischer Hansen

  • 1Rigshospitalet, Copenhagen University Hospital and Institute of Preventive Medicine, The Copenhagen Trial Unit, Center for Clinical Intervention Research, Copenhagen, Denmark.

Cardiology
|March 31, 2011
PubMed

Insights

Short-term clarithromycin use increased sudden cardiovascular death risk in stable coronary heart disease patients not on statins. This finding highlights a critical safety concern for this patient group.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • The CLARICOR trial identified excess mortality associated with clarithromycin in patients with stable coronary artery disease.
  • Understanding the mechanisms behind this excess mortality is crucial for patient safety.

Purpose of the Study:

  • To investigate the potential mechanisms contributing to clarithromycin-induced excess mortality.
  • To differentiate between sudden and non-sudden cardiovascular deaths in relation to clarithromycin use.

Main Methods:

  • Utilized Cox regression analyses to compare out-of-hospital deaths (proxy for sudden death) with in-hospital deaths.
  • Examined 189 cardiovascular deaths to classify them as sudden or non-sudden based on the place of death.

Main Results:

  • A significant association was found between the place of death and its classification as sudden or not-sudden.
  • Excess mortality in the clarithromycin group was predominantly linked to sudden cardiovascular death.
  • This increased risk was specifically observed in patients not taking statins at trial entry (HR: 2.61, 95% CI: 1.69-4.05).

Conclusions:

  • Short-term clarithromycin administration is significantly associated with an elevated risk of sudden cardiovascular death.
  • This risk is particularly pronounced in stable coronary heart disease patients who are not using statins.
  • The findings underscore the importance of considering statin use when evaluating the safety of clarithromycin in cardiovascular patients.
Abstract

Related Concept Videos

Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...